Therapeutic and Adverse Effects of SSRIs

A project submitted by

Imtiazur Rahman

ID: **13146002**

Session: **Spring 2013**

to

the Department of Pharmacy

in partial fulfillment of the requirements for the degree of

Bachelor of Pharmacy (**Hons**.)

BRAC University

Dhaka, Bangladesh

March 2018

Dedicated to all the children who suffer from mental illness.

Certification Statement

This is to certify that the review project titled “Therapeutic and Adverse Effects of SSRIs” submitted for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.) from the Department of Pharmacy, BRAC University is completely my own work under the supervision of Mr. Ashis Kumar Podder, Senior Lecturer, Department of Pharmacy, BRAC University. Throughout the review project, I have given proper credits where I have used the language, ideas or writings of others.

Signed,

_____

Countersigned by the supervisor,

_____

Acknowledgements

I would like to express my deepest appreciation to my supervisor, Mr. Ashis Kumar Podder (Senior Lecturer) for his constant guidance and support, without which this work would not have been possible. For his encouragement, I am deeply grateful. I am also very grateful to all the faculties of Pharmacy Department of BRAC University for guiding me through all these years.

I would like to thank my parents for the patience and their support throughout this project work. I am forever in their debt.

Abstract

A great number of the world's population suffers from the depressive disorder. Mental illness, depression, fear and stress-related illnesses are frequently treated with SSRI or selective serotonin reuptake inhibitor. Adverse effects like suicidal tendencies and mental breakdowns cannot be ignored along with beneficial effects of SSRIs. A thorough review and analysis of articles and documents published by relevant researchers and organizations were done to utilize information for every section of this project work. The review showed that the detrimental effects range from cardiac dysfunction to suicidal tendencies and violent behaviors. Depressive disorders if not treated, may result in more harmful circumstances. The review work also evaluated the superior therapeutic effects of SSRI drugs over other anti-depressants claimed by different researchers. Although it is not yet clear whether adverse effects like life-threatening behavior occurs due to SSRIs or not, doctors should make sure that depressive and nervous signs of illness are properly tested before prescribing SSRI medicine. Doctors and caregivers should also closely monitor potential adverse effects and changes in the patient's behavior and personality during and after the treatment.

Keywords: SSRI, adverse effect, therapeutic effects, depression, suicidal tendencies, discontinuation syndrome.

Table of contents

List of acronyms

ADE: Absorption, Distribution, and Elimination

AE: Adverse Effect

CBT: Cognitive-Behavioral Therapy

CDRS-R: Children's Depression Rate Scale-revised

FDA: Food and Drug Administration

GI: Gastrointestinal

Na/K ATPase: Sodium-Potassium Adenosine Triphosphatase

OCD: Obsessive-Compulsive Disorder

RCT: Randomized Control Trials

RDBPCT: Random Double-Blind Placebo Clinical Trial

HDRS: Hamilton Depression Rating Scale

SSRI: Selective Serotonin Reuptake Inhibitors

STAR*D: Sequenced Treatment Alternatives to Relieve Depression

WHO: World Health Organization

List of tables

List of figures

1. Introduction

Depression in children and adolescents is very prominent but often remains unrecognized in the society. It affects 2 % of pre-teen children and 5 to 8 % of juveniles (Son & Kirchner, 2000). In Bangladesh, it is more prominent in adults, mostly in women.

According to the FDA, the early 2000s have seen an increase in incidences of suicide in adolescents and children. The new generation of antipsychotics and antidepressants failed in their efficacy and the use of SSRI drugs have become a common practice even though their use faces a lot of controversy. SSRI stands for Selective Serotonin Reuptake Inhibitor. They function by their capability to stop the recovery of serotonin back into the presynaptic nerve ending, resulting in increased levels of serotonin in the synaptic cleft. Depression is associated with low levels of serotonin, therefore, leading to decreasing feelings of well-being. This makes the patient feel a constant state of unhappiness. The growth of the levels of serotonin in the synaptic cleft, allows more serotonin to bind to the postsynaptic cleft elevating feelings of well being. A lot of research have been done to determine the side effects and compare the usefulness of the drugs to know if the drugs have any long-term effects or not. The recognized durability of the SSRIs and fallen concern about cardiotoxicity have caused this radical change in their use. However, the Food and Drug Administration (FDA) has increased major concerns about the safety of the SSRIs in pediatric populations, according to a critical review on 2005 by the FDA (Scahill, Hamrin, & Pachler, 2005)

Now-a-days, mental illness is regarded as one of the rising problems of this generation and is very much in children and adolescents. If the treatment is not done accordingly, this kind of mental illness can cause harm to the children as well as to those around them, which includes parents, relatives, classmates and friends. This paper contains a comprehensive review through several research articles to obtain proper knowledge about the effects of SSRI on children.

1.1. Aim of this Project

The author of this project work is interested to evaluate the adverse effects and therapeutic effects of SSRI drugs as they are highly effective in treating depression but also have several harmful and severe adverse effects and also to create awareness among the people

about the proper use of these drugs**.**

1.2. SSRIs

SSRIs are drugs that function by inhibiting the absorption of serotonin in the brain, making them more abundant for brain cells to utilize (Rhoten, 2002). SSRIs are antidepressant medications which are classified on the basis of their uniqueness and activation capability of brain neurotransmitters. Example of this class of medications include fluoxetine, escitalopram, citalopram, fluvoxamine, sertraline and paroxetine, etc (Korczak, 2013).

1.2.1. Invention

The initial experimentation with fluoxetine, demonstrating 5-HT reuptake inhibitory effects, was done in Dr. David Wong's laboratory on May 8, 1972. On July 24 of the very year, fluoxetine was identified as the strongest and selective inhibitor of 5-HT. In reference to the clinical development of fluoxetine, an Investigational New Drug Application (IND) was filed to the FDA in 1976. The initial open phase II research with zimelidine, which is also a SSRI, was announced during that time. After fruitful clinical research with the drug, a New Drug Application for fluoxetine was listed with the FDA in 1983. It was allowed for marketing in 1987. Pharmaceutical company Eli Lilly got the patent for fluoxetine (Prozac) in 1988 (Stanford, 1999).

1.2.2. Source of Serotonin

In the living body, the forerunner of serotonin is tryptophan. Tryptophan is a basic amino acid. Its exclusion from the eating regimen of man or creatures is instantly trailed by tissue squandering. The body needs 6 to 9 mg of tryptophan per kilogram body weight to obstruct negative nitrogen adjust. A typical individual's body turns over about 1% of the utilized tryptophan into serotonin. This transformation is obtained in two stages. The hydroxylase enzyme gives the hydroxyl part that binds to the tryptophan in position 5, and 5-hydroxytryptophan is framed. In the following stage, the enzyme decarboxylase expels a carboxyl group, and the result is 5-hydroxytryptamine, or serotonin (Sirek & Sirek, 1970).

1.2.3. Binding Sites of SSRIs

No less than 4 particular subtypes of 5-HT receptors have been distinguished in brain

membranes. Every one of the 5-HT binding site subtypes can be marked by H-5-HT. Radio ligand restricting examinations have obviously demonstrated that aggregate 5-HT official as characterized by H-5-HT is heterogeneous in the rodent frontal cortex. In an analysis done in the research center, computer examination of medication competition bends with overall H-5-HT binding demonstrates that 5-HT rivalry with H-5-HT to add up to 5-HT destinations is reliable with homogenous receptor populace. 8-OH-DPAT is around 10000 times specific for the 5-HT site versus all other known 5-HT binding site subtypes. So, it is viably used to halt H-5-HT binding to the 5-HT binding sites without influencing the binding in general (Meltzer, Heuring, Mauk, Ph, & Kocsis, 1986)**.** If the binding does not occur then serotonin in the synaptic cleft increases because of overactivation of postsynaptic receptors.

1.3. Mechanism of Action

Serotonin is a type of chemical messenger, otherwise known as a neurotransmitter that is released from one neuron into the synapse to be transmitted to another neuron to conduct impulses. A synapse is a space between two neurons. After the serotonin has performed its function, it is either destroyed by the receiving neurons or reabsorbed into the releasing neuron. The function of SSRI antidepressants is to inhibit the reuptake of the serotonin leading to an abundant of serotonin growth in the synapse. In theory, the higher the amount of serotonin available and present at a time in the synapse, greater the activation of the nervous system (Roten, 2002).

Serotonin has been known to lead to problems associated with various physiological attributes such as disposition, tension, rest, temperature, hunger, sexual conduct, eating conduct, developments, gastrointestinal (GI) motility, etc of patients (Stahl, 1998). These interactions are affected by changes in enzymes and several binding sites in the body. Enzymes are affected when they are energy-creating Na/K ATPase. Binding sites are afflicted straight by the serotonin. These binding sites can show any of two actions, either by expanding serotonin binding at the sodium site or to lower serotonin binding at the SSRI site (Stahl, 1998).



Fig.**1.3.1:** The serotonin transporter illustrates the binding sites for serotonin and also for the SSRI**.**



Fig.**1.3.2**: Serotonin is binding to the transporter after giving its effect**.**



Fig.**1.3.3:** SSRI binds on the transporter molecule and hampers transporter compatibility for serotonin. (Stahl, 1998)

The serotonin transporter in Fig. 1.3.1 illustrates binding sites for serotonin also for the SSRI. Sodium binding to its site of action on the molecule rises transporter compatibility for serotonin (also known as positive allosteric modulation), allowing serotonin to bind to the transporter (Fig. 1.3.2 sodium binding not displayed for directness). Although, SSRI binding to its site of action (also possess the site for binding sodium on the molecule) dampers transporter compatibility for serotonin (also called negative allosteric modulation), thus inhibiting serotonin binding to the transporter (Fig. 1.3.3) (Stahl, 1998).

Affinity is the degree to which a substance tends to combine with another, therefore, in this case, it is the tendency of the substrate to bind to its active site in order to bring about conformational changes.

1.4. SSRI Drugs

Each medication consisting of the drug classes, SSRI has an interesting pharmacological profile as well as ADE (Absorption, distribution and elimination) profile. These differences could have a very wide and varied effect on all patients taking the medications. Those suffering from hepatic and renal dysfunction may face some adverse effects. Patients who are in the practice of polypharmacy run the risk of facing side effects and adverse effects. Polypharmacy is the practice where a single patient takes a wide range and dosages of medications due to the presence of various illnesses at the same time. Using SSRI medication along with polypharmacy is a very risky practice as there could be drug-drug interactions which would bring about undesirable effects. Some of the undesired effects include the heightened activity of drug leading to toxicity, lower than optimal activity due to antagonistic effects which eliminate any beneficial effects of the drug and lastly formation of different toxic compounds which could lead to toxicity or death (Valuck, 2004).

Some of the widely used SSRI drugs around the world are:

- Fluoxetine
- Fluvoxamine
- Paroxetine
- Citalopram

It is recommended that SSRIs should be used for the therapy of depression. However, a contradiction to this is the statement and clinical proof that this medication does not affect all patients in the same uniform manner. A study has shown that only about 40-50% of patients (mostly children) treated with SSRI medication achieve satisfactory results after initial treatment. For some of the patients, there is no effect either positive or negative as a result of the treatment. The remaining patients face several side effects that will eventually lead to the cessation of treatment using SSRIs. (Wessling & Ramsberg, 2008).

1.4.1. Fluoxetine

One of the most widely prescribed and used SSRI is fluoxetine. Actually it is a stronger blocker of 5-HT2C receptors than other serotonin reuptake inhibitors. Inhibition of 5-HT2C

receptors balances brain norepinephrine and dopamine frameworks, which cause actuation and weight reductions. It is regarded that fluoxetine has active equity which can lead to several complications, for example, in restless patients, it is not uncommon to experience a sleeping disorder and feelings of unsettling. This property can be used in a different class of patient, those who experience a lack of energy. For them, this could eliminate feelings of lethargy and laziness allowing them to be more active in their day to day activities instead of constantly feeling the need to lie down and sleep. Fluoxetine has a dynamic metabolite which is known as norfluoxetine. The pharmacologic movement of norfluoxetine like that of its parent compound fluoxetine. This corresponds to its half-life of 4 – 16 days (Carrasco & Sandner, 2005).

In a study conducted using 24 children about 50% multiple behavioral side effects after tested with fluoxetine (Riddle et al., 1990).

Table.1.4.1: Behavioral side effects in 24 Children and Juveniles treated with Fluoxetine. (Riddle et al., 1990)

Side effects	**Number of affected patients**
Motor restlessness	N=11
Sleep disturbance	N=11
Social disinhibition	N=6
Subjective sensation of excitation	N=3

There behavioral side effects happened as followed:

11 children who suffered from motor restlessness, 10 of them also had sleep disturbances. 11 children who had sleep disturbance, 10 of them felt motor restlessness. 6 children dealing with social disinhibition, all 6 suffered from motor restlessness and 5 suffered from sleep disturbance. Of the 3 children with a subjective urge of excitation, all experienced sleep disturbances and 2 experienced motor restlessness and social disinhibition. Overall, 2

patients had four of these behavioral side effects, 2 patients had three side effects while 8 patients had two side effects. (Riddle et al., 1990)

1.4.2. Paroxetine

Paroxetine is the principle SSRI stimulant which has been seeming to limit norepinephrine take-up. An investigation that observed how norepinephrine and serotonin transporter work on Human Transporter Transfected Cells in serum from patients, found that desipramine or paroxetine, the two drug types executed as serotonin or norepinephrine, take-up inhibitors, especially at estimations of 40 mg or higher of paroxetine (Ciraulo & Shader, 2011). Muscarinic impacts are predominantly seen in charge of the repulsive reactions of the tricyclic antidepressants that lead to problems with medications of this class making it very troublesome for some patients. It is possible for an unassuming level of anticholinergic sedation to advance an immediate improvement of sleeping disorder and tension while diminishing the initiating activities. Paroxetine also prevents the reuptake of noradrenaline more than the other various antidepressants of this class. This effect is altogether less powerful than that of the tricyclic drugs, for instance, desipramine and amitriptyline. However the effect is more pronounced compared to that of various SSRIs (Carrasco & Sandner, 2005). Examination of paroxetine's adequacy in the treatment of children and juveniles'mental issues has yielded negative outcomes in three randomized control trials (Korczak, 2013).

Paroxetine was assessed in an 8-week, multi-focus, placebo controlled trial in 275 youth who were experiencing depressive disorder and were between the ages of 12 and 18 years (Keller et al., 2001). Subjects were administered with either placebo, imipramine, or paroxetine. In spite of the fact that paroxetine indicated more noteworthy changes than placebo, the distinction was not measurably critical on the essential result of the outcome. In a study, five subjects in the paroxetine aggregate displayed self-destructive signals; two demonstrated intensified depressive behavior; animosity, indiscretion, and related manifestations. All these symptoms were detailed in one of the subjects. Among the subjects given placebo, one patient displayed passionate obligation, while one other patient demonstrated a compounding of depression and related side effects (Scahill et al., 2005).

1.4.3. Citalopram

Citalopram is well known amongst selective SSRIs. Its most particularly distinguished property is the lack of activation and sedating property. Citalopram has basically no impact on noradrenergic receptors. Citalopram has mainly three active metabolites, which may keep on exerting pharmacological effects once citalopram has been utilized SSRIs (Carrasco & Sandner, 2005). This activity of the metabolites exerting the same effects as the parent drug provides the lack of activation and sedation when taking the drug.

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) examination was intended to survey viability of medicines in commonly available citalopram and to guarantee the conveyance of sufficient medications to cure ailments. The primary outcome was remission of depressive characteristics. Citalopram was chosen as a delegator SSRI as there are no adverse symptoms experienced when the drug use is discontinued. This demonstrates safety in aged and medically weak patients as a result of the following advantages of, once a day dosing, flow dose adjustment steps and agreeable drug-drug interaction profile which gave only a few favorable results (Trivedi et al., 2006)**.**

The STAR*D trial gave some fascinating outcomes. The outcomes proposed that those who did not respond to the trial had increased reaction rates. These reaction rates were higher than reaction rates experienced when the same trial was carried out by exchanging drugs. The examination results show that the trial was not influenced to give false results as there was no bias towards any one trial parameter (Ciraulo & Shader, 2011).

A study done in 2004 used the first placebo-controlled tests of citalopram trial in children and juveniles with depression. The examination was continued for more than two months. In this period of randomized trial, a total of 174 youngsters was chosen. Their ages extended from the vicinity of 7 and 17 years, citalopram showed a normal change of 36% deviation from the standard on the essential measure of depression severity. This is different from a normal change of 28% change for patients treated with placebo. Despite the fact that the contrast between groups was little, it was factually critical and demonstrated a positive outcome for the medication (Scahill et al., 2005).

Citalopram has been related to reduce libido and may be linked with the generally higher level of sexual dysfunction in contrast to sertraline when used to treat similar symptoms.

These symptoms may pronouncedly affect the patients' adherence to treatment and therefore, affect the overall activity of the drug (Korczak, 2013).

Citalopram shows a considerably negative result in another analysis compared to studies of the same nature conducted by other scientists. Studies which have used citalopram have showed an increased effect, therefore it can be concluded that this alternative treatment option has a high efficiency (Wessling & Ramsberg, 2008).

In a 8 week long random double-blind placebo clinical trial, 174 depressed youth ages in the vicinity of 7 and 17 years were given citalopram. The result showed an important increase in benefits experienced by individuals. Even though this result is positive it does not have significant clinical importance as a European, multicenter RDBPCT of citalopram in 244 depressed young people demonstrated no benefits from the active medication. These two studies have different contradictory results (Henry, Kisicki, & Varley, 2012).

1.4.4. Sertraline

Sertraline has critical dopamine up-take blocking impacts, in spite of the fact that these are significantly weaker than its serotonin uptake blocking properties. It is adequately powerful at blocking dopamine uptake, therefore, prolonging effects of dopamine in the body. Sertraline may be quite useful in patients suffering from troubling and unnatural types of depression. Along with fluoxetine, sertraline is considered as one of the SSRIs with the highest dopaminergic (D2) compatibility. A greater D2 compatibility means better results and fewer depressive attributes (Carrasco & Sandner, 2005).

Sertraline has not consistently been able to show a positive effect. It tends to skew largely either positively or negatively in various studies. According to BMJ Clinical Evidence, the best medication with the best effects is not known. Another point which has not been verified is how long the effect will continue or how long the patient would undergo the treatment without any adverse effects (Wessling & Ramsberg, 2008).

In a 12-week study, 112 youth with OCD, ages extending from 7 to 17 years, were randomized to four treatment conditions: placebo treatment, sertraline alone, cognitive-behavioral therapy (CBT) alone or sertraline with CBT. The basic outcome measure showed there was a change on the Children's Yale-Brown Obsessive-Compulsive Scale.

Every one of the three dynamic medicines was better than placebo treatment and the joined treatment bet any active treatment alone. Another test was performed where two multicenter RDBPCTs were converged to create the information for one extensive investigation of sertraline in depressed kids and adolescents. In this examination, 376 depressed youth, from 6– 17 years, were randomized to either sertraline or placebo treatment for 10 weeks. A measurably noteworthy advantage from sertraline was noted on the CDRS-R, however the clinical importance of the change was hard to decipher due to the results being quite close, therefore inconclusive (Henry et al., 2012).

2. Methodology

The review paper is constructed following a systematic method that includes reviewing the electronic information of valid sources.

Information was found through analysis of journal articles of relevant and well-known institutions and publications. The information present in this paper were gathered from published research articles.

Information on each topic was studied thoroughly before putting it on the paper. This entire paper abides by all kinds of ethical rules of information usages. Information was paraphrased to avoid plagiarism and similarity of information.

3. Results

Both positive and negative effects regarding the use of SSRI drugs have been observed after studying admissible articles related to different malicious effects of SSRIs. They manifest effects like akathisia, discontinuation syndrome, and different types of adverse effect. Studies also depict that they also show a high-level of potency and they have high therapeutic effects over placebos and other antidepressants.

3.1. Adverse Effects

Adverse effects (AE) related with selective serotonin reuptake inhibitor (SSRI) treatment of young people are real worry. The adverse effects of SSRI treatment have been a major concern due to the harm it poses on pertinent tissue. This concern was highlighted in logical writing, the media and inside the U.S. Food and Drug Administration (FDA). The

biggest problem has been due to increased self-destructive conduct and propensities complemented by these medications Youngsters naturally utilize drugs more quickly than grown-ups. The way they perceive drug intake could legitimize more successive medication application for children. It may bring about more issues with drug withdrawal. All this eventually might lead to discontinuation of medication use and increased AEs. There are still various unpublished investigations that depend on the discoveries that have not been exhibited as clinical trial investigations of SSRIs. These tend to report bringing down AE rates in case arrangements and group reports on account of case choice along with selective reporting differences. This includes the recurrence of withdrawal from SSRI treatment, which is relatively high. The arrangement studies and reports which have given these results have been obtained through follow-up phone interviews and reports of real test drug trials (Safer & Zito, 2006).

With the arrival of Prozac in 1986 (US), proof for a connection between selective serotonin reuptake inhibitors (SSRIs) and suicidality and self-harm and suicidal tendency started to amass from a scope of various sources. The potential for these genuine adverse impacts was first perceived amid the advancement of drugs influencing the serotonergic framework in trials demonstrated since its discovery. Their physiological impacts and collaborations are not completely known, but rather have been theorized as being because of the generation of Akathisia coming about because of sudden compensatory lowering of serotonin and dopamine levels activated by the nervous system changing in accordance with the medications (Hamilton & Opler, 1992; Hyman, 2001).

Akathisia is a neurologically determined type of disturbance and fretfulness. At its most severe episode there are clear, grievous, distracting, forceful and self-destructive contemplations that are related with brutal and self-destructive practices. Also previously mentioned concerns encompassing despondency. News of issues with SSRIs has met with protection. To put it brazenly, there are two conflicting cases about SSRIs and the dangers of suicide. They either lessen the urges of suicidal tendencies or increase their destructive impacts (Liebert & Gavey, 2009).

Most antidepressants cause manic behavior. This is a recognized adverse impact in the FDA-endorsed publications of all antidepressants. Additionally, *The Lancet* (a weekly

peer-reviewed general medical journal) portrayed how there are self-destructive temptations related with fluoxetine use. This is a very damaging side effect of the medication which is counterproductive. (Breggin, 2003).

Behavioral adverse impacts include hyperactivity, crabbiness, threatening vibe, disinhibition, passionate liability and self-harm. These adverse effects happen in approximately 10-25% of youth, according to Elbe et al. (2014). Class specific speculation becomes difficult as discontinuation rates may be higher due to adverse effects (from 0 to 9%) (Garland, Kutcher, Virani, & Elbe, 2016).

The risk-benefit balance for fluoxetine in the youngster and youth depressive illness is positive, unlike most SSRIs, making them suitable for use. The exception, however includes, teenagers used to other types of SSRIs. These teenagers should be checked for adequacy and adverse effects, particularly for suicide-related ideas and behavioral unfriendly impacts (e.g. Actuation occasions) is basically imperative before changing treatment (Garland, Kutcher, Virani & Elbe, 2016).

As indicated by Dr. Breggin, akathisia is like being tormented from inside. It resembles the shrieking of chalk down a board, just it is going down the patient's spinal section. The offended parties discovered on their studies, interior organization reports demonstrating that organization asked for examines had delivered prove that several volunteers had antagonistic responses to Paxil, including endeavored suicide. Likewise, the WHO has expressed that Paxil has the most noteworthy rate of withdrawal adverse encounters of any antidepressants (Roten, 2002).

SSRIs purposely interfere with different kinds of medications for serotonin syndrome. This presents as jerking, tremors, inflexibility, fever, perplexity, or unsettling. For fluvoxamine, suicide endeavor was independently recorded as rare. On account of fluoxetine, self-destructive ideation was recorded as a deliberate report not turned out to be medicine related. On account of sertraline, self-destructive ideation and endeavor were recorded independently as rare.

Researchers expressed in their examination that, SSRIs provide 1,600 anecdotes of violence and 200 SSRI-related lawsuits (Kauffman, 2009).

Another RCT was done and since the subsequent period for this randomized controlled trials was short, and sample numbers were generally little. So genuine adverse impacts were probably going to be few. When adverse effects do start to show, researchers who are conducting these trials will in this manner anticipate that reviewers of these effects will attract awareness regarding them, alongside information accessible from different sources that propose that genuine adverse impacts may happen. Of 93 patients treated with paroxetine, 11 had genuine adverse events, contrasted with 2 out of 87 in the placebo treatments. The researchers exhibited no factual investigation (Jureidini et al., 2004).

3.2. Discontinuation Syndrome

The term discontinuation, as opposed to withdrawal disorder, is favored to maintain a strategic distance from any misguided judgment about medication reliance or addiction. There is no certain proof that the SSRIs and related antidepressants have a critical reliance risk or show improvement of a reliance disorder as indicated by globally acknowledged criteria (either DSM– IV or ICD– 10) (Haddad & Anderson, 2007). Antidepressants are not considered addictive as they are not related to drug searching practices in the patients and have no clinically critical potential to cause reliance. Stopping side effects do likewise happen amid quick decreasing of therapeutic effects particularly if there is a considerable diminishing in dose. Indications additionally resolve quickly upon restoring the first SSRI. The seriousness of the discontinuation syndrome is not the same for every SSRI. It is by all accounts identified with the drug's half-life. The shorter the half-life the faster the medication will be dispensed with and the more typical will be the discontinuation response (Hosenbocus & Chahal, 2011).

3.3. Drug-Drug Interaction

SSRIs can interact with CYP1A2, CYP2D6, CYP2C19, and CYP3A4 to a varying degree. Severe toxic effects have been described after overdoses of citalopram in the presence of moclobemide, also an antidepressants. Fluoxetine and norfluoxetine are recognized to be strong inhibitors of CYP2D6, an enzyme which contributes to the metabolism of many tricyclic antidepressants and other psychotropic drugs. In this respect, the S-enantiomers of fluoxetine and norfluoxetine display a similar potency. Paroxetine and its metabolite, M2, are potent inhibitors of CYP2D6. Another clinical interaction study with terfenadine, a

CYP3A4 substrate, confirms that paroxetine has little effect on the kinetics of this H1-receptor antagonist and therefore cannot be considered as a CYP3A4 inhibitor (Stanford, 1999).

4. Discussion

Discussion in this paper is leading towards an established argument about the usage of SSRI and different effects of it. There are also researchers and scientists who are studying these topics on multiple grounds and some are divided on how they should be prescribed or whom they should be prescribed to. Although, most of them argue that therapeutic effects of SSRI overrun the various side and adverse effects but these adverse and side effects cannot be overlooked as they are very frighteningly dangerous.

4.1. Opinions of the scientists supporting therapeutic benefits

Due to the lack of clarifications in the initial reports, scientists were not able to determine if suicidal tendencies were potentiated by the accidental availability of drugs to the patients. The picked studies in this report have been incorporated due to their representativeness in connection to the entire populace of youth passing on by suicide, instead of those who died due to any consumption of SSRIs**.** By amassing information from six populace investigations of individual pre-adult suicides that inspected introduction to SSRIs, authors found that it was especially uncommon for SSRIs to have been utilized before suicide in this more youthful populace (Dudley, Goldney, & Hadzi-Pavlovic, 2010).

Sertraline a widely used SSRI drug has demonstrated adequacy for the treatment of juvenile depression, with a particular positive RCT. Each study detailing more noteworthy advantages for these drugs over that accomplished by placebo treatment (Korczak, 2013).

Whittington et al. (2004) found that, except for fluoxetine, the incorporation of unpublished information modified the general discoveries to such an extent that the dangers exceeded the advantages of treatment with many drugs. Considering the general confinements of small impact sizes, and the potential suicidality chance, the revelation of all discoveries seems important (Saypol, 2005).

A study in the year 2003 provided details regarding a multicenter, double-blind, placebo-controlled trial of sertraline including 376 children ages 6 – 17 years experiencing

significant depression. Following 10 weeks of treatment, sertraline was related to a moderate of 47% change in depressive manifestations, reducing severity compared to a 40% average decrease in the placebo group. This distinction between the medication and placebo treatment was factually great. A tremendous result is seen, yet evidently it is unassuming. Adverse effects included two suicide endeavors in the sertraline gathering and two in the placebo treatment group showing the ineffectiveness of the placebo in those patients. Three patients in the sertraline group had self-destructive ideation, while one patient demonstrated expanded violence and aggressive emotional episodes (Scahill et al., 2005).

There are no clear answers in the writing to the topic of regardless of whether the discouraged child and pre-adult patients ought to be treated with SSRIs. SSRIs are convincing in reducing or discarding depression, potential issues of tolerance of drugs over psychotherapy to adolescents, and disclosures that SSRIs have accepted a section in the general decline in pre-grown-up suicide rates which can be restricting with various examinations. The contention over the utilization of antidepressant medications has been elevated by moral concerns with respect to unpublished information. Of specific concern was the disclosure of inside documentation at a drug organization instructing the withholding of information of a specific SSRI, paroxetine (Saypol, 2005).

Firstly, controlled clinical trials differentiation of any psychotropic medication with a placebo treatment will regularly deliver proof of an example of central nervous system adverse medication impacts with mental side effects that are particular for the medication and not for the placebo treatment. For instance, SSRI-antidepressants and amphetamine-like components both tend to create a continuum of central nervous system provocation. This physical provocation will be related to mental signs that range from gentle euphoria and touchiness to depression and lunacy, and at last to expanded rates of both violence and suicidality. Secondly, studies of reports found in FDA articles additionally showed that specific medications are related to particular examples of outrageous mental and behavioral responses. Even non-mental pharmaceuticals have been involved in causing depression and suicidality. Isotretinoin (Accutane), a drug used to treat extreme skin disease, has caused depression and suicidality as exhibited in various clinical reports and in singular contextual investigations. In some clinical cases, depression ceased with the suspension of treatment

and repeated with reinstitution of treatment. Thirdly, numerous physical issue also influences mental demeanors and conduct. Hyperthyroidism and in addition overdoses of thyroid hormone can expand anxiety, touchiness, and different feelings that the individual would not normally experience. This can also prompt unusual behavioral variations. There are, also, numerous comparable cases which can contribute to this kind of behavioral variation such as hormones. For example, testosterone and cortisone can influence moods and emotional behavior. More to the point, accidental brain damage to the frontal lobes and surgical lobotomy more often than not weaken judgment, moral limitation and self-reflection. The character of the individual is frequently seen as changed and declined **(**Breggin, 2003**).**

In any case, patients who had self-destructive manifestations preceding antidepressant treatment, will probably have those indications even after the treatment. In their cases, drug therapy was related to the repeat of a recognized issue. Whether connection is global or a causal, it is not clear. Regardless of all these studies, there is huge variation with studies from the FDA (Gualtieri & Johnson, 2006).

4.2. Opinions of the scientists concerned about the adverse effects

From the year 2003, fewer children and teenagers have been recommended with antidepressants in primary treatment, especially the CSM-contraindicated drugs. The percentage of fluoxetine and non-SSRI antidepressants has not risen in a while, proposing that they are not recommended like the CSM-contraindicated antidepressants. In view of the information gathered, it can be assessed that roughly one of the contraindicated antidepressants since the CSM direction was distributed. The rate data found in a study for CSM-contraindicated drugs demonstrated a 48% decrease between the year of 2002 and 2004, which is higher than the data found in the earlier studies (39%) for a similar period of time (Murray, Thompson, Santosh, & Wong, 2005).

SSRIs may influence the concentration of fundamental neurotransmitter substances in the brain and can influence the placebo treatment in some ways if not careful. This has to be considered when translating a mean distinction amongst medication and placebo treatment. In any case, it is improbable that depressed patient has a huge misleading impact and it has demonstrated that the placebo treatment reaction has been steady for a long time. Indeed,

even in view of the predefined negligible limits for clinical importance, the impacts of SSRIs did not have a clinically important impact on depressive manifestations. As, per the meta-investigations, SSRIs fundamentally increase the danger of both genuine and non-genuine adverse effects found in the light of the aggregate number of trials, just a moderately predetermined number of trials provided details regarding each of our pre-characterized results. This builds the danger of selective result announcing biases. All the included trials were surveyed at high danger of biasness. It might be argued that the biased risk appraisal frequently will prompt no trials with generally safe of biases. Comparable bias risk evaluations have been utilized as a part of a few past precise surveys. The Hamilton Depression Rating Scale (HDRS) found the middle value of impacts. Subsequently, it cannot be concluded that SSRIs do not have clinically noteworthy consequences for all discouraged member. Such as certain severely depressed patients compared with slightly depressed patients any clinical research result will have different adverse effect. Some patients may profit by given treatment despite the fact that substantial research outcomes have demonstrated that these treatments are average and ineffectual or even dangerous (Jakobsen et al., 2017).

Researchers revealed that half of the youngsters treated with 20 – 40 mg of fluoxetine for OCD or depressive manifestations showed some behavioral side effect and that these unfavorable impacts resolve quickly with SSRI cessation (Riddle et al. 1991). In reports of higher controlled trials, PAEs were accounted for in 17% to 37% of kids getting SSRI treatment (Wilens et al. 2003).

Researchers including Dr. Breggin, have examined the lives of numerous people who affected by psychoactive medications, for example, SSRIs, SNRIs, and benzodiazepines have perpetrated act of violence that were completely unfamiliar to their own character and contradictory to their earlier behavior. It is also, understood that the illicit utilization of stimulant medications, for example, methamphetamine and cocaine, can be related to neurotic responses and brutality. As suggested by Preda et al, the SSRIs, and psychedelic drugs, for example, lysergic corrosive diethylamide (LSD) may cause psychosis through comparable impacts on serotonin receptors (Breggin, 2003).

5. Conclusion

This paper accumulated most of the studies done by the researchers which are relevant to this topic. From the studies we observed that SSRIs in most of the cases cause severe mental health problems and also other bodily dysfunctions. They also have some adverse effects which can lead to injuries or even death. The suicidal tendency is one of the issues that has been discussed earlier in this project. Our finding is that SSRI class of drugs has therapeutic and adverse effects which cannot be overlooked though it does have efficacy and therapeutic effects which is far better in treating depression than any other type of antidepressants. So, there should be limitations for prescribing this medication to the patients. The FDA and European drug administration have enforced precautionary measures and have recommended to provide prior warning before prescribing SSRIs. However, there are very few alternatives which are as effective as SSRIs. That is why discontinuation of SSRI usage among the patients is not possible to happen overnight. In my opinion, more warnings should be given beforehand and also the labels and packets containing these drugs should also contain more cautionary warnings so that, patients could understand more about the risk associated with this drug.

References

Breggin, P. R. (2003). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. *International Journal of Risk and Safety in Medicine*, *16*(3), 31–49.

Carrasco, J. L., & Sandner, C. (2005). Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: An overview. *International Journal of Clinical Practice*, *59*(12), 1428–1434. http://doi.org/10.1111/j.1368-5031.2005.00681.x

Ciraulo, D. A., & Shader, R. I. (2011). *Pharmacotherapy of depression: Second edition*. *Pharmacotherapy of Depression: Second Edition*. http://doi.org/10.1007/978-1-60327-435-7

Dudley, M., Goldney, R., & Hadzi-Pavlovic, D. (2010). Are adolescents dying by suicide taking SSRI antidepressants? A review of observational studies. *Australasian Psychiatry*, *18*(3), 242–245. http://doi.org/10.3109/10398561003681319

Garland, E. J., Kutcher, S., Virani, A., & Elbe, D. (2016). Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*, *25*(1), 4–10.

Gualtieri, C. T., & Johnson, L. G. (2006). Antidepressant Side Effects in Children and Adolescents. *Journal of Child and Adolescent Psychopharmacology*, *16*(1–2), 147–157. http://doi.org/10.1089/cap.2006.16.147

Haddad, P. M., & Anderson, I. M. (2007). Recognising and managing antidepressant discontinuation symptoms. *Advances in Psychiatric Treatment*, *13*(6), 447–457. http://doi.org/10.1192/apt.bp.105.001966

Henry, A., Kisicki, M. D., & Varley, C. (2012). Efficacy and safety of antidepressant drug treatment in children and adolescents. *Molecular Psychiatry*, *17*(12), 1186–1193. http://doi.org/10.1038/mp.2011.150

Hosenbocus, S., & Chahal, R. (2011). SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*, *20*(1), 60–67.

Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., … Gluud, C. (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. *BMC Psychiatry*, *17*(1). http://doi.org/10.1186/s12888-016-1173-2

Jureidini, J. N., Doecke, C. J., Mansfield, P. R., Haby, M. M., Menkes, D. B., & Tonkin, A. L. (2004). Efficacy and safety of antidepressants for children and adolescents. *BMJ : British Medical Journal*, *328*(March 2006), 879–883. http://doi.org/10.1136/bmj.328.7444.879

Kauffman, J. M. (2009). Selective Serotonin Reuptake Inhibitor (SSRI) Drugs: More Risks than Benefits? *American Physicians and Surgeons*, *14*(1), 7–12.

Korczak, D. J. (2013). Use of selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness. *Pediatrics and Child Health*

(Canada), *18*(9), 1–6. Retrieved from https://onlinereview.cps.ca/papers/use-of-SSRIs-for-child-adolescent-mental-illness/print_ready.pdf

Leo, J. (2006). The SSRI Trials in Children: Disturbing implications for academic medicine. *Ethical Human Psychology and Psychiatry*, *8*(1), 29–42

Liebert, R., & Gavey, N. (2009). "There are always two sides to these things": Managing the dilemma of serious adverse effects from SSRIs. *Social Science and Medicine*, *68*(10), 1882–1891. http://doi.org/10.1016/j.socscimed.2009.02.047

Ludwig, J., Marcotte, D. E., & Norberg, K. (2009). Anti-depressants and suicide. *Journal of Health Economics*, *28*(3), 659–676. http://doi.org/10.1016/j.jhealeco.2009.02.002

Meltzer, H. Y., Heuring, R. E., Mauk, M. D., Ph, D., & Kocsis, J. D. (1986). Serotonin Receptor Subtypes : Biochemical, Physiological, Behavioral, and Clinical Implications Analysis of 5-HT1 Binding Site, *22*(3), 3–7.

Murray, M. L., Thompson, M., Santosh, P. J., & Wong, I. C. K. (2005). Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. *Drug Safety*, *28*(12), 1151–1157. http://doi.org/10.2165/00002018-200528120-00009

Olfson, M., Marcus, S. C., Weissman, M. M., & Jensen, P. S. (2002). National trends in the use of psychotropic medications by children. *J Am Acad Child Adolesc Psychiatry*, *41*(5), 514–521. http://doi.org/10.1097/00004583-200205000-00008

Riddle, M. a., King, R. a., Hardin, M. T., Scahill, L., Ort, S. I., Chappell, P., … Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. *Journal of Child and Adolescent Psychopharmacology*, *1*(3), 193–198. http://doi.org/10.1089/cap.1990.1.19

Roten, R. D. (2003). Selective Serotonin Reuptake Inhibitors: A Critical Look at the Antidepressants and an Assessment of Potential Liability Faced by their Manufacturers. (2003 Third Year Paper), Harvard University, Retrieved from http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852159 Accessed on: November 17, 2017 10:25:33 AM EST.

Safer, D. J., & Zito, J. M. (2006). Treatment-Emergent Adverse Events from Selective Serotonin Reuptake Inhibitors by Age Group: Children versus Adolescents. *Journal of Child and Adolescent Psychopharmacology*, *16*(1–2), 159–169. http://doi.org/10.1089/cap.2006.16.159

Saypol, E. (2005). Child and Adolescent Depression : Should Antidepressants Be Used in Treatment ? *Graduate Student Journal of Psychology*, *7*, 29–36.

Scahill, L., Hamrin, V., & Pachler, M. E. (2005). The use of selective serotonin reuptake inhibitors in children and adolescents with major: Depression. *Journal of Child and Adolescent Psychiatric Nursing*, *18*(2), 86–89. http://doi.org/10.1111/j.1744-6171.2005.00015.x

Sirek, A., & Sirek, O. V. (1970). Serotonin: a review. *Canadian Medical Association Journal. 102*(8), 846–9.

Son, S. E., & Kirchner, J. T. (2000). Depression in Children and Adolescents. *American Family Physician*, *62*(10), 2297–2308. Retrieved from https://www.aafp.org/afp/2000/1115/p2297.html

Stahl, S. (1998). Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate ... Serotonin receptors and pathways mediate therapeutic effects and side effects. *Journal of Affective Disorders*, *51*(4).

Stanford, S. C. (1999). *Selective Serotonin Reuptake Inhibitors (SSRIs)*. *R.G. Landes Company*.

Timothy E. Wilens, M.D., Joseph Biederman, M.D., Anne Kwon, M.S., Rhea Chase, B.A., Laura Greenberg, B.A., Eric Mick, Sc.D., and Thomas J. Spencer, M. . (2003). Psychiatric Adverse Events in Children and. *Journal of Child and Adolescent Psychopharmacology*, *13*(2), 143–152.

Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., … Fava, M. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. *American Journal of Psychiatry*, *163*(1), 28–40. https://doi.org/10.1176/appi.ajp.163.1.28

Valuck, R. (2004). Selective serotonin reuptake inhibitors: A class review. *P and T*, *29*(4), 234–243.

Wessling, A., and Ramsberg, J. (2008). Depression: The review of antidepressants. *Dental and Pharmaceutical Benefits agency.* 1(1).

Whittington, C., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *The Lancet*, *363*, 1341–1345. https://doi.org/10.1016/S0140-6736(04)16043-1